Attached files
file | filename |
---|---|
EX-99 - PRESS RELEASE - CEL SCI CORP | cvm_ex99.htm |
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (date of earliest event reported): June 5, 2017
CEL-SCI CORPORATION
(Exact
name of Registrant as specified in its charter)
Colorado
|
001-11889
|
84-0916344
|
(State
or other jurisdiction
|
(Commission File
No.)
|
(IRS
Employer
|
of
incorporation)
|
|
Identification
No.)
|
8229
Boone Boulevard, Suite 802
Vienna, Virginia
22182
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code: (703) 506-9460
N/A
(Former
name or former address if changed since last report)
Item
8.01 Other Events
On June
5, 2017 the Company issued a press release, filed as Exhibit 99,
announcing that it has responded to the U.S. Food and Drug
Administration’s (FDA) most recent
communication.
Item 9.01
Exhibits
Exhibit
|
|
Number
|
Description of
Document
|
|
|
June 5,
2017 Press Release.
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date:
June 5, 2017
|
CEL-SCI CORPORATION |
|
|
|
|
|
|
|
By:
|
/s/
Patricia B.
Prichep
|
|
|
|
Patricia B.
Prichep
|
|
|
|
Senior Vice President of Operations |
|